MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of short-term...
$77,777K
Proceeds from stock
option exercises
$7,460K
Proceeds from employee
stock purchase plan
$458K
Net cash provided by
investing activities
$38,390K
Net cash provided by
financing activities
$7,918K
Canceled cashflow
$39,387K
Net decrease cash,
cash equivalents and...
-$4,037K
Canceled cashflow
$46,308K
Stock-based compensation
$12,054K
Prepaid expenses and
other assets
-$7,837K
Other receivable
-$6,137K
Collaboration receivable
(payable), net
$3,238K
Non-cash operating lease
expense
$130K
Amortization of debt issuance
costs
$56K
Depreciation
$4K
Purchases of short and
long-term investments
$39,387K
Net cash used in
operating activities
-$50,345K
Canceled cashflow
$29,456K
Net loss
-$42,673K
Accrued expenses and
other liabilities
-$28,349K
Accounts payable
-$5,737K
Inventory, net
$2,060K
Accretion of investments
$862K
Accounts receivable, net
-$120K
Back
Back
Cash Flow
source: myfinsight.com
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)